Sign In
Buy SDGR
$15.14
-0.210 (-1.37%)
At Close: Jul 31, 2026
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
07:00pm, Wednesday, 26'th Feb 2025
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago.
Schrödinger to Participate in Upcoming Investor Conferences
08:30am, Monday, 24'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside cha
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26
08:30am, Wednesday, 12'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close.
Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last?
04:45am, Thursday, 23'rd Jan 2025
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
07:00am, Monday, 13'th Jan 2025
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:30am, Tuesday, 17'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company's c
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
08:30am, Monday, 18'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger broadens and accelerates predictive toxicology initiative.
Schrodinger price target raised to $28 from $27 at Goldman Sachs
05:17pm, Wednesday, 13'th Nov 2024
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving b
Schrodinger price target raised to $28 from $27 at Goldman Sachs
05:17pm, Wednesday, 13'th Nov 2024
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving b
Schrödinger (SDGR) Q3 2024 Earnings Call Transcript
10:51am, Tuesday, 12'th Nov 2024
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates
09:06am, Tuesday, 12'th Nov 2024
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago.
Schrödinger Reports Third Quarter 2024 Financial Results
06:50am, Tuesday, 12'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the third quarter of 2024 and provided a business update.
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
06:45am, Tuesday, 12'th Nov 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
06:01am, Wednesday, 23'rd Oct 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Sym
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:30am, Thursday, 17'th Oct 2024
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on Octob
